Therefore, the AL513318.2/hsa-miR-26a-5p/SLC6A8 regulatory network may serve as a novel prognostic biomarker and potential therapeutic target for NSCLC treatment. This evidence concerns the gene SLC6A8 and non-small cell lung carcinoma.